Full-Time
Commercial Marketing
Life Sciences
Posted on 5/9/2026
Verily
1,001-5,000 employees
Precision health tech leveraging data science
Compensation Overview
$149k - $223k/yr
No H1B Sponsorship
Dallas, TX, USA + 1 more
More locations: San Bruno, CA, USA
In Person
 Growth & Marketing (2) |
|---|
| , |
- Bachelor’s degree in Business, Marketing, or a related field.
- 8-12+ years in Product Marketing, Commercial Strategy, Management Consulting, or a related Commercial role.
- Proven experience in B2B HealthTech, Life Sciences, or SaaS. At least 5-7 years of specific experience selling to, marketing to, or working within the Life Sciences vertical is required.
- Experience specific to Top 40 Pharma is strongly preferred.
- Demonstrated ability to enable sales or business development teams within complex, multi-stakeholder B2B sales cycles.
- Segment & Buyer Persona Expertise: Become the definitive internal expert on the Life Sciences landscape, including macroeconomic trends, regulatory shifts, and the competitive environment. Define and refine the "Economic Buyer" and "Technical Influencer" personas. Deeply understand the "why" and "how" behind the segment’s purchasing decisions to anticipate objections and accelerate the sales cycle.
- Problem-First Messaging & Portfolio Synthesis: Clearly land buyer segment needs and establish how Verily’s capabilities and solutions directly solve their business needs. Create value propositions that span across Verily’s product pillars, positioning our full suite of solutions as a unified answer to segment challenges. Articulate how Verily’s solutions reduce complexity and speed up the realization of business outcomes for clients.
- The "Pitch-in-a-Box" & Customer-Specific Customization: Develop and maintain the foundational Life Sciences commercial toolkit, including segment-specific playbooks, high-stakes pitch decks, and ROI/TCO calculators. Tailor this core messaging and content appropriately for all customer pitches and touchpoints.
- Funnel Acceleration: Identify bottlenecks and develop messaging interventions to progress opportunities through the funnel. Identify where marketing activities (e.g., demand gen campaigns, webinars, events, CABs, whitepapers, publications, etc.) would effectively and efficiently accelerate the sales motion, and work with the Marketing org to recommend, prioritize, and operationalize these activities. Identify high-growth sub-segments and white-space opportunities within the vertical. Influence the product roadmap by translating customer feedback and market gaps into clear commercial requirements.
- AI-Driven Scalability & Delivery Ownership: Build and maintain "scalable sources of truth" using modern AI tools and frameworks to amplify output at scale. Own the delivery of commercial assets and strategic results from conception to completion, including cross-functional coordination and supplemental market research.
- Strong comfort with developing and delivering sales and marketing messages to multiple audiences, from C-Suite to engineering levels. Must be excellent in creating high-quality, client facing deliverables in content and presentation.
- Proactively identify gaps, develop approaches, recommend based on market research, and launch and iterate quickly to drive impact for the sales team, bringing teams along through the process.
- Experience with streamlining a process and delivering clear documentation, tracking, and training where needed.
- Ability to use data to justify commercial strategies and measure the impact of marketing activities on the sales pipeline.
- Proven track record of managing complex, cross-functional projects with high-stakes dependencies (e.g., Legal, Regulatory, Clinical).
Verily Life Sciences uses data science and clinical expertise to improve health outcomes through precision health. It combines medical, lifestyle, and environmental data to tailor interventions, offering products like the Baseline Platform for clinical research and COVID-19 testing, care management solutions, and medical devices. It differentiates itself by integrating diverse data at scale, pursuing health equity through Onduo, and collaborating with public sector partners while maintaining strong data security and privacy. The goal is to uncover new health insights and bring precision health to everyone, improving health outcomes across populations.
Company Size
1,001-5,000
Company Stage
Late Stage VC
Total Funding
$3.8B
Headquarters
San Francisco, California
Founded
2015
Simplify's Take
What believers are saying
- $300M funding from Series X Capital ends Alphabet control, boosts AI expansion.
- Nvidia integration accelerates multimodal data processing in Pre platform.
- Samsung HIMSS26 partnership unlocks wearable data for real-world evidence generation.
What critics are saying
- Sloan lawsuit exposes HIPAA breaches affecting 25,000 Onduo patients since 2017.
- HHS OCR fines hit Verily for failing 60-day breach notifications until 2026.
- Tempus steals NIH contracts as Verily's privacy scandals erode partner trust.
What makes Verily unique
- Verily Pre platform integrates Galaxy Watch8 data with AI for clinical research.
- Verily Workbench on AWS enables compliant AI analysis for NIH All of Us.
- Segmed partnership adds 150 million de-identified imaging exams to Pre Exchange.
Help us improve and share your feedback! Did you find this helpful?
Your Connections
People at Verily who can refer or advise you
Benefits
Company Equity
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↓ -1%2 year growth
↑ 0%Verily Health has announced that Verily Workbench, its scalable trusted research environment for biomedical data analysis and AI development, is now generally available on Amazon Web Services. The platform enables researchers to analyse healthcare data with built-in compliance and integrated AI tools. Workbench offers zero cloud cost markup, allowing organisations to use existing AWS accounts and negotiated rates. The platform includes native integration with NVIDIA AI tools and supports multicloud operations across AWS and Google Cloud Platform. Researchers can access free standard tier accounts through Verily's Exchange solution. The platform currently serves life sciences, health system and government customers, including the NIH's All of Us Research Programme, which supports over 20,000 researchers worldwide. Verily holds SOC 2 Type 2 and ISO/IEC 27001 certifications.
Dallas-Based Verily raises $300M, ending Alphabet's controlling stake. Verily graduated from Google X 10 years ago as one of Alphabet's earliest "Other Bets," focusing on breakthrough science and health tech innovation. Its new round was led by Series X Capital, with participation from Alphabet, UCHealth, the University of Colorado Anschutz, and other investors. The lobby of Verily's headquarters at Cypress Waters in Dallas. [Photo: Verily] Dallas-based Verily has raised a new $300 million investment round led by Series X Capital, with participation from Alphabet, UCHealth, the University of Colorado Anschutz, and other investors, for the next phase of its precision health AI strategy. With this funding round, Alphabet will now be a significant minority investor in Verily, while no longer having a controlling stake. "Today is an important step in our mission to bring the promise of precision health to everyone," said Stephen Gillett, chairman and CEO of Verily,. "From research to care, our customers need solutions that bring the best of clinical and scientific rigor together with AI to deliver the next generation of healthcare - one that is as precise as it is personal." "Series X Capital, Alphabet, UCHealth, the University of Colorado Anschutz and our many investors will be fantastic partners in this transformation of healthcare," Gillett added in a statement. With the investment, Verily has transitioned its legal structure from an LLC to a corporation, and will now operate as Verily Health Inc. The company said it aims to boost its AI-native precision health platform strategy and roadmap to help customers streamline their healthcare data, while modeling and deploying actionable intelligence into research and care workflows. Verily is headquartered in the Cypress Waters development in Dallas, just southeast of Coppell. The company relocated its HQ from South San Francisco in 2024, bridging its East and West Coast operations in North Texas while maintaining its presence in the Bay Area. Using AI to transform healthcare. Recently, Verily has established several commercial partnerships, including a new collaboration with Samsung's Galaxy Watch to help life sciences customers advance clinical research through biomarker development on the Pre platform. The company has also announced a strategic partnership with Salesforce for the integration of the Verily Pre Platform with Agentforce Health to fuel enterprise precision health solutions. Verily said the new partnerships are strengthened by its recent collaboration with UCHealth, the University of Colorado Anschutz, and RefinedScience, who are using the Verily Pre platform for AI-driven research and care transformation. Gideon Yu, founder and managing partner of Series X Capital, said his firm "was established in collaboration with Google's X, The Moonshot Factory, to scale moonshot technologies into consequential, world-changing companies." He added that his firm is "extremely excited to lead this milestone round for Verily, as they drive commercial momentum as a leader in precision health." 'A generational opportunity' Graduating from Google X 10 years ago as one of Alphabet's earliest "Other Bets," Verily focuses on breakthrough science and health tech innovation. "At Alphabet, we applaud Verily's tenacity in using technology to address longstanding challenges in the healthcare industry," said Ruth Porat, president and. chief investment officer at Alphabet and Google. "Bringing in new investors, alongside Alphabet's ongoing involvement, enables Verily to further scale the business to help improve patient outcomes and lower the cost of healthcare delivery through their AI health platform." Richard Zane, MD, UCHealth chief medical and innovation Officer, said that collaborating with Verily to craft a data framework "creates a generational opportunity" to improve medicine. "This collaboration helps unlock the long-promised potential of personalized care," Zane added, "benefiting our patients and, ultimately, all patients. It will save lives, and we're eager to get started." Other recent moves by Verily. Last October, Verily launched a new consumer health app, Verily Me, designed to close gaps in care and enable people to stay informed and engaged in their health journey over time. Last April, Verily received a $14.7 million grant from The Michael J. Fox Foundation for Parkinson's Research. The grant's goal is to generate a comprehensive molecular dataset to advance Parkinson's disease research. Track Dallas-Fort Worth's business and innovation landscape with its curated news in your inbox Tuesday-Thursday. One quick signup, and you're done. R E A D N E X T. * The Last Word: Arete Health CEO On a First-of-Its-Kind Health and Wellness Program for Dallas Creatives Creatives Care Dallas brings virtual care, behavioral health, 2,000+ medications with zero copay, and more to Dallas County's gig workers. The community initiative is powered by Arete Health Shield in partnership with the Dallas Music Office. * Calendar: Not-to-Miss Events for Innovators in Dallas-Fort Worth North Texas has plenty to see, hear, and watch. Here are its editors' picks. Plus, you'll find more selections to "save the date." * Alphabet-Owned Verily Launches AI-Powered App to Manage Healthcare and Personalize Insights Unveiled at HLTH USA 2025, the Dallas-based precision health company's Verily Me app blends clinical guidance and AI-driven tools to help people stay informed, connected, and proactive in managing their health. * North Texas Innovation Is Boundary-Breaking. Nominations for the Awards That Prove It Close Sept. 12 D CEO and Dallas Innovates have expanded The Innovation Awards 2026 with more individual and company categories this year. Now is your chance to be part of the region's defining recognition for innovators. * SVP Dallas Names Catherine Cuellar as Its Next CEO A familiar figure in Dallas arts, civic innovation, and public service, Cuellar will succeed longtime CEO Tony Fleo following a months-long search as Social Venture Partners Dallas plans its next 25 years. Share via:
Exclusive: verily raises $300M, sheds Alphabet's majority control. Health tech correspondent. Verily has raised $300 million in new, outside funding that ends parent company Alphabet's controlling position in the healthcare innovation company, Endpoints News has learned... Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Dallas, TX – March 19, 2026 – Verily today announced a $300 million investment round led by Series X Capital, with participation from Alphabet, UCHealth, the University of Colorado Anschutz and other investors, to advance the next phase of its precision health AI strategy.
Samsung partners with Verily Life Sciences to utilize Galaxy Watch8 data. At HIMSS26, Verily Life Sciences announced a partnership with Samsung Electronics to combine Galaxy Watch8 with Verily's precision health platform to further clinical research. By Jessica Hagen | March 10, 2026 | 11:59 AM Photo: Courtesy of Samsung LAS VEGAS - At the 2026 HIMSS Global Health Conference & Exposition here, Samsung Electronics America announced a partnership with Verily Life Sciences to connect Verily's precision health platform, Pre, with Samsung's Galaxy Watch8 to monitor real-world populations and generate evidence to assist in research for life sciences and governments. Pre is an AI-enabled offering that processes structured and unstructured multimodal data for AI deployment, workflow orchestration and analytics. The partnership will integrate sensor data from the Galaxy Watch and make it accessible in its Viewpoint Evidence tool, built on the company's Pre platform. "Sponsors will use Verily Pre data solutions including Refinery for data harmonization and Workbench for analysis, modeling and activation. Verily will provide AI/ML-based analytics and digital measure expertise, paired with comprehensive clinical trial support across regulatory, development, operations and compliance," Verily said in a statement. The companies aim to help life sciences organizations and governments accelerate research using health analytics and customer-grade wearable data. The partners say the collaboration will allow researchers to combine Verily's longitudinal datasets from consented participants with Samsung's data, customize research capabilities by allowing sponsors to run their own studies, and recruit and engage Samsung users for research participation. As part of the collaboration, the partners said they will further explore jointly developing new solutions for clinical research.